RAYMUND J. WELLINGER, Ph.D.
Canada Research Chair in Telomeres Biology
Director, Microbiology and Infectiology Department
Phone: 819 821-8000 ext 75214
Fax: 819 820-6831
The results from these efforts are expected to shed light on the reasons why cancerous human cells have a virtually unlimited potential for division and therefore appear immortal, while normal cells have a predetermined lifespan and are mortal. Such insights could yield essential clues for new anti-cancer therapies.
Prof. Wellinger obtained his Ph.D. (Molecular Biology) from the Swiss Institute for Experimental Cancer Research (ISREC), which is associated with the University of Lausanne (Switzerland, 1986). He then performed post-doctoral work at the Fred Hutchinson Cancer Research Center (Seattle, USA, 1993).
He acted as Vice-President Research of the start-up biotech company Telogene, of which he also was a co-founder. Furthermore, Prof. Wellinger is involved in several international collaborations, has authored five patents and published several research communications in the most prestigious scientific journals, such as Cell, Nature and Science.
Due to his internationally leading stature, Prof. Wellinger is called upon to serve on evaluation committees for research grants at the National Institutes of Health (NIH, USA) and the Canadian Institutes of Health Research (CIHR). He also serves as a member of the Board of Directors of the Fonds de Recherche en Santé du Québec (FRSQ). Finally, Prof. Wellinger is a frequently sought after reviewer and advisor for the publication of research articles in the world's leading journals, such as Science, Cell, Nature, Genes and Development, Molecular and Cellular Biology, and Proceedings of the National Academy of Sciences (USA).
- 2000, Co-founder of the biotech company Télogène, which raised 2.5 M$ of private investments.
- 2001,Chercheur-National Award by the Fonds de Recherche en Santé du Québec (FRSQ).
- 2005, Co-investigator of the Sherbrooke University Functional Genomics’ Laboratory financed by Genome Canada/Genome Quebec (10.5 M$ over four years).
- 2000-2007, Research Grants from the Canadian Institutes of Health Research and the National Cancer Institute of Canada fora total of 350,000$/year for7 years.